Although evidence is increasing against routine screening for prostate cancer (PCa) at the population level, early prostate-specific antigen (PSA) tests are still the primary examine for men with an elevated PCa risk in order to make a decision of advanced examination, such as digital rectal examination, biopsy, and magnetic resonance imaging [1]. The gene discussed is KLK3; the disease is prostate cancer.